+1 (704) 266-3234

Anti Malarial Drugs Market- Growth, Trends, And Forecast (2020 - 2025)

Published on: Jan 2020 | From USD $4250 | Published By: MORDOR INTELLIGENCE | Number Of Pages: 111

Market Overview

Antimalarial drugs are used for the treatment and prevention of malaria infection. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and underdeveloped countries. According to the ÒWorld Malaria Report 2018Ó by World Health Organization (WHO), there were an estimated 219 million cases and nearly 435,000 malaria-related deaths in 2017. Hence, the high prevalence of malaria is driving the growth of this market. Other factors like an increase in awareness initiatives by Governments and research for new anti-malarial drugs and therapies are also helping this market grow.
However, side-effects of anti-malarial drugs and the presence of counterfeit and substandard drugs are restraining the growth of this market.

Scope of the Report

Antimalarial drugs are designed to treat malaria in individuals or prevent the infection in individuals who have no immunity for the infection

In the report, a detailed analysis of the Antimalarial drugs Market is provided. The market is evaluated by collating revenues generated across segments, categorized by drug class, malaria type, mechanism of action and geography.

Key Market Trends

Artemisinin compounds segment is expected to register high growth in the forecast period

According to the World malaria report, 2017 by the World Health Organization, an estimated 409 million treatment courses of artemisinin-based combination therapy (ACT) were procured by countries in 2016 which was an increase from 311 million in 2015. Over 69% of these procurements were reported to have been made for the public sector. The number of ACT treatments distributed by national malaria control programs (NMCP) in Africa to the public sector increased from 192 million in 2013 to 198 million in 2016. Most of the NMCP distributions of ACTs in 2016 occurred in the WHO African Region.

Owing to these factors, this market segment is expected to grow in the forecast period

The Middle East and Africa is one of the largest markets

According to the World Health Organization (WHO), there were an estimated 219 million cases of malaria worldwide in 2017, out of which WHO African Region carried a disproportionately high share of the global malaria burden. In 2017, the region contributed 92% of malaria cases and 93% of malaria deaths. The WHO Eastern Mediterranean Region was home for nearly 2% of the global malaria cases. Moreover, out of the total USD 2.7 billion investment in 2016 for the treatment and prevention of malaria, nearly 74% was spent in the WHO African Region.

Owing to these factors, the Middle East and Africa region is expected to have one of the largest shares in the total anti-malarial drugs market.

Competitive Landscape

The majority of the anti-malarial drug are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. These global players are mostly based in developed countries like United States, United Kingdom, France, Germany, and Japan. Asia-pacific is also witnessing the emergence of some small players which has helped the market growth and increased competitiveness.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Malaria in Developing and Under Developed Countries
4.2.2 Awareness Iniatives undertaken by Governments
4.2.3 Increasing Research for New Drugs and New Combinations Therapies
4.3 Market Restraints
4.3.1 Side Effects of Anti-malaria Drugs
4.3.2 Presence of Counterfeit and Substandard Antimalarial Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Class
5.1.1 Aryl aminoalcohol compounds
5.1.2 Antifolate compounds
5.1.3 Artemisinin compounds
5.1.4 Other Drug Types
5.2 By Malaria Type
5.2.1 Plasmodium Falciparum
5.2.2 Plasmodium Vivax
5.2.3 Plasmodium Malariae
5.2.4 Plasmodium Ovale
5.3 By Mechanism of Action
5.3.1 Treatment for Malaria
5.3.2 Prevention from Malaria
5.4 Geography
5.4.1 North America US Canada Mexico
5.4.2 Europe Germany UK France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Mylan Labs
6.1.2 Cipla
6.1.3 GlaxoSmithKline
6.1.4 Novartis
6.1.5 Roche Holding AG
6.1.6 Bayer AG
6.1.7 Lincoln Pharmaceuticals
6.1.8 Strides Pharma Science
6.1.9 Glenmark Pharmaceuticals
6.1.10 Alliance Pharmaceuticals


Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

The market engineered data is verified and validated by a number of experts, both in-house and external.

After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $4250
USD $4750
USD $6000
USD $7500


  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.